Omega Diagnostics Group Plc (LON:ODX)‘s stock had its “corporate” rating reiterated by FinnCap in a report released on Tuesday. They currently have a GBX 30 ($0.39) target price on the stock. FinnCap’s price target points to a potential upside of 50.00% from the stock’s current price.

Shares of Omega Diagnostics Group Plc (LON:ODX) opened at GBX 19.55 ($0.26) on Tuesday. Omega Diagnostics Group Plc has a 52-week low of GBX 16.60 ($0.22) and a 52-week high of GBX 28.01 ($0.37).

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at

Omega Diagnostics Group Plc Company Profile

Omega Diagnostics Group PLC is a medical diagnostics company. The Company’s segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers.

Receive News & Stock Ratings for Omega Diagnostics Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group Plc and related stocks with our FREE daily email newsletter.